CB — Chubb Limited

The market is constructive but not euphoric: Q2 core EPS of $7.26 beat consensus, the combined ratio improved to 83.8%, and Berkshire Hathaway's 8.88% stake adds a powerful endorsement. Offsetting that are decelerating premium growth (North America Commercial P&C premiums -2.3%) and signs of a softening commercial casualty pricing cycle, leaving the consensus at more Hold/Moderate Buy than strong Buy and the stock just below its 50-day average.

Revenue has grown steadily on a YoY basis—Q2 2026 revenue rose 6.3% to $15.82B from $14.88B a year earlier, following Q1 2026's 10.2% jump. That is deceleration, and it is intentional: Chubb is passing on poorly priced property and E&S business. Net income is lumpy—Q1 2025 was a $1.33B trough, Q4 2025 benefited from a $3.21B quarter—but the last two quarters show consistent $2.3B-$2.9B net income. Operating margins are running in the low-to-mid 20s excluding the Q1 2025 anomaly, so this is a quality story with a growth-speed problem, not a deterioration into a cyclical trough.

As of 2026-08-27, CB trades at 11.9x trailing EPS of $28.53 and roughly 12.2x next-FY EPS of $27.69, both right in line with its 5-year average P/E of 12.4x. Price-to-sales is 2.10x versus a 2.03x 5-year average, and the PEG is 0.49, though the growth input is flattered by what looks like a rebound year. Net-net, valuation is fair—not cheap enough to call a bargain, not rich enough to dismiss.

The price is roughly matching the earnings power: EPS is expected to dip modestly next fiscal year (consensus $27.69 vs TTM $28.53), so the market is not pricing in an earnings breakout. The playbook is mean-reversion/quality: if Chubb keeps a sub-85 combined ratio, strong investment income, and disciplined capital returns, the stock should grind toward the ~$358 analyst target; if pricing softens enough to hurt the combined ratio, the current multiple leaves no cushion—that's why BofA's $314 bear case exists.

As of 2026-08-27, RSI stood at 42.1—soft but neither oversold nor overbought. Price is 2.1% below its 20-day SMA and 2.4% below its 50-day SMA, while holding 4.1% above its 200-day SMA, so the intermediate trend is a pullback within a longer uptrend. A trader would want either a reclaim of the 50-day or an RSI in the low 30s before adding; an investor can treat the 200-day area (~$325) as the nearer support.

• P&C pricing cycle softening: property rate increases decelerating and casualty rate increases no longer outpacing 6-12% loss-cost inflation.
• Elevated Treasury yields support net investment income, a key earnings driver for P&C carriers.
• Peak Atlantic hurricane season in Q3 2026; Chubb already absorbed $475M pretax cats in Q2.
• Low beta (0.39) makes CB a defensive equity proxy in risk-off periods.
• Stable regulatory/capital environment; 33rd consecutive annual dividend increase signals board confidence.

• Q3 2026 earnings in late October—watch whether premium discipline caps growth and whether cats stay within budget.
• Berkshire Hathaway's new 8.88% stake could lead to further disclosures or a more constructive shareholder base.
• Capital returns: $7.5B buyback authorization and recurring dividend increases.
• If commercial P&C pricing firms or casualty rates re-accelerate, growth could re-rate the stock.

• Softening casualty pricing with loss costs still rising could squeeze combined ratios despite underwriting discipline.
• Significant catastrophe losses in Q3 (hurricane season) above the $475M Q2 baseline.
• Premium growth already slowing; excessive pullback in E&S/large property could turn into market-share loss.
• Interest-rate/investment-market volatility can dent book value and realized gains.

Chubb is a best-in-class P&C franchise with an 83.8 combined ratio, solid cash generation, rising dividends, and now a marquee Berkshire stake. The reason it is only Neutral rather than Bullish is that the top line is deliberately flat-to-down in places, the industry pricing cycle is turning softer, and the stock is neither cheap nor showing an imminent earnings inflection. It's a reasonable compounder to own at a fair price, but not a high-conviction buy at $338.

Applied a justified forward P/E of ~12.8x to consensus next-FY EPS of $27.69, a slight premium to CB's 5-year average of 12.4x justified by its superior combined ratio, negative accruals, and Berkshire endorsement; cross-checked by applying 12.4x to TTM EPS of $28.53 (= $353.8), giving $354.